BioGeneration Ventures (BGV) is an early-stage venture capital firm specializing in European biotech, medtech, and diagnostics companies. Their strategy involves investing in therapeutic innovations with a strong scientific foundation that address significant unmet medical needs, and actively building companies from scientific discovery through to product development.
75% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $46.2M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$400M
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Citryll | Series B | $85M | Dec 2024 |
 Brenig Therapeutics Inc. | Series A | $65M | Jul 2024 |
 Scenic Biotech | Series A | $31M | Mar 2022 |
 Mellon Medical | Series B | $4M | Jun 2020 |
Top Co-Investors
EI Ventures1 shared
Vesalius Biocapital1 shared
INKEF Capital1 shared
Oxford Science Enterprises1 shared
OrbiMed1 shared
Torrey Pines Investment1 shared
Johnson & Johnson Innovation1 shared
Forbion1 shared
Novartis Venture Fund1 shared
Pureos Bioventures1 shared
Seventure Partners1 shared
Last updated: 10 April 2026